Administration of TLR2 agonist Pam3CSK4 or TLR4 agonist LPS markedly diminished the expression of GSC markers, implying a TLR-dependent differentiation; dual application of Pam3CSK4 and TMZ resulted in an increased GBM cell sensitivity to chemotherapy [86]. Here, TLR4 is linked to glioblastoma.